PARP Inhibitors Improve Outcomes, QOL in Breast Cancer
Not only are PARP inhibitors proving to be an efficacious treatment for patients with metastatic breast cancer, but they're also improving quality of life, too.
When given an oral agent such as a PARP inhibitor, patients with metastatic breast cancer reported that they felt more in control of their life, something that Jennifer Litton, MD, of the The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology, called a “game changer.”
While these agents improve quality of life, they are also proving to be clinically efficacious, too. Both the EMBRACA trial (studying talazoparib in patients with metastatic breast cancer with a BRCA mutation) and the OLYMPIAD trial (studying olaparib for patients with metastatic breast cancer with a BRCA mutation) are showing that PARP inhibition therapy can improve treatment outcomes compared to standard-of-care chemotherapy in this patient population.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
